The article by Alain Moren (coordinator) and Jim McMenamin (president of I-MOVE) was published on the occasion of the project’s closing.
I-MOVE+ (Integrated Monitoring of Vaccines Effects in Europe) is a European platform to measure and compare the effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in older people. This European Union project – Horizon 2020 encompasses 24 EU Member States and has allowed to build a vast network of collaboration in these countries.
The I-MOVE+ objectives were as follows:
Analyze and compare the effectiveness and impact of current vaccines and vaccination strategies against seasonal influenza and pneumococcus.
Assist EU/EEA countries and beyond in making informed decisions on immunisation policy, in order to provide the best possible quality of life for the most vulnerable people and assist the least favoured countries in developing an effective and efficient vaccination programme
Ultimately, develop a sustainable platform of general practitioners, hospitals and laboratory networks that can share validated methods for evaluating vaccine performance.
Published in Impact (a review of open and free scientific reports), the article summarizes the main findings of the three-year project and highlights the importance of public funding to conduct vaccine evaluation studies independently of vaccine producers.